Pfizer: FDA approves copy of Roche's Herceptin
(CercleFinance.com) - The US Food and Drug Administration has approved Pfizer's biosimilar to Roche's blockbuster cancer treatment Herceptin, the drugmaker said on Tuesday.
The FDA has approved Trazimera for the treatment of human epidermal growth factor receptor-2 (HER2) overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
Approximately 15%-30% of breast cancers and 10%-30% of gastric cancers are HER2-positive.
Trazimera was also approved for use in the EU in July 2018 for the treatment of HER2 breast cancer and HER2 metastatic gastric or gastroesophageal junction adenocarcinoma.
Pfizer shares are currently up 0.7% at 41.8 dollars in New York after the news.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The FDA has approved Trazimera for the treatment of human epidermal growth factor receptor-2 (HER2) overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
Approximately 15%-30% of breast cancers and 10%-30% of gastric cancers are HER2-positive.
Trazimera was also approved for use in the EU in July 2018 for the treatment of HER2 breast cancer and HER2 metastatic gastric or gastroesophageal junction adenocarcinoma.
Pfizer shares are currently up 0.7% at 41.8 dollars in New York after the news.
Copyright (c) 2019 CercleFinance.com. All rights reserved.